Marketing authorisation application accepted for biosimilar to treat neutropenia

The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) of a biosimilar version of Neulasta (pegfilgrastim) to treat chemotherapy-induced neutropenia from Cinfa Biotech. Read more

6 Oct 2017 12:28 News